Patents by Inventor Till Maurer

Till Maurer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-?-synuclein antibodies and methods of use
    Patent number: 9732148
    Abstract: The present invention relates to anti-alpha-synuclein (anti-?-synuclein) antibodies and methods of using the same.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: August 15, 2017
    Assignee: Genentech, Inc.
    Inventors: Gai Ayalon, Till Maurer
  • USP7 inhibitor compounds and methods of use
    Patent number: 9573899
    Abstract: 2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 21, 2017
    Assignee: Genentech, Inc.
    Inventors: Robert Blake, Paola Di Lello, Jason Drummond, Christine Johanna Heideker, Lorna Kategaya, Till Maurer, Jeremy M. Murray, Chudi Ndubaku, Richard Pastor, Lionel Rouge, Vickie Tsui, Ingrid E. Wertz, Kebing Yu
  • USP7 INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20160272588
    Abstract: 2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: March 18, 2016
    Publication date: September 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Robert Blake, Paola Di Lello, Jake Drummond, Christine Johanna Heideker, Lorna Kategaya, Till Maurer, Jeremy M. Murray, Chudi Ndubaku, Richard Pastor, Lionel Rouge, Vickie Tsui, Ingrid E. Wertz, Kebing Yu
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20160108113
    Abstract: The present invention relates to anti-alpha-synuclein (anti-?-synuclein) antibodies and methods of using the same.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 21, 2016
    Applicant: GENENTECH, INC.
    Inventors: Gai Ayalon, Till Maurer
  • Bicyclic oligopeptides
    Patent number: 7101848
    Abstract: The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of: (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and (b) a second cyclic group which is formed by an amide bonding of an amino acid with the ?-carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a); and to the use of such bicyclic oligopeptides for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: September 5, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Olivier Potterat, Ruediger Streicher, Klaus Wagner, Till Maurer, Juergen Mack, Stefan Peters
  • Bicyclic oligopeptides
    Publication number: 20040072736
    Abstract: The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of:
    Type: Application
    Filed: July 17, 2003
    Publication date: April 15, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Olivier Potterat, Ruediger Streicher, Klaus Wagner, Till Maurer, Juergen Mack, Stefan Peters